ରୁକ୍ସୋଲିଟିନିବ

ରୁକ୍ସୋଲିଟିନିବ
Clinical data
Pronunciation	Jakafi /ˈdʒækəfaɪ/ JAK-ə-fye
Trade names	Jakafi, Jakavi
Synonyms	INCB018424, INC424
AHFS/Drugs.com	monograph
MedlinePlus	a612006
data	EU EMA: yes; US DailyMed: Ruxolitinib;
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	95%
Protein binding	97%
Metabolism	Liver (mainly CYP3A4-mediated)
Elimination half-life	2.8-3 hours
Excretion	Urine (74%), faeces (22%)
Identifiers
	IUPAC name (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;
Chemical and physical data
Formula	C17H18N6
Molar mass	୩୦୬.୩୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3;
	InChI InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 ; Key:HFNKQEVNSGCOJV-OAHLLOKOSA-N ;
(verify)

ରୁକ୍ସୋଲିଟିନିବ, ବିକ୍ରୟ ନାମ ଜାକୋଫି ଏବଂ ଜାକାଭି, ଏକ ଔଷଧ ଯାହା ମାଇଲୋଫାଇବ୍ରୋସିସ୍, ପଲିସାଇଥେମିଆ ଭେରା (ପିସିଭି/ PCV) ଏବଂ ଗ୍ରାଫ୍ଟ-ବନାମ-ହୋଷ୍ଟ ରୋଗର (ଜିଭିଏଚଡି/ GvHD) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ପିସିଭି ରୋଗରେ ହାଇଡ୍ରୋକ୍ସିକାର୍ବାମାଇଡ ଯଥେଷ୍ଟ ନ ହେଲେ ଏବଂ ଜିଭିଏଚଡିରେ କୌଣସି ଔଷଧ କାର୍ଯ୍ୟକ୍ଷମ ନ ହେଲେ ଏହା ବ୍ୟବ‌ହାର କରାଯାଏ ।^[୧] ଏହା ପାଟି ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥ୍ରୋମ୍ବୋସାଇଟୋପେନିଆ, ରକ୍ତହୀନତା, ସ୍ୱଳ୍ପ ନିଉଟ୍ରୋଫିଲ, ରକ୍ତସ୍ରାବ, ଯକୃତ ସମସ୍ୟା ଏବଂ ଅସ୍ୱାଭାବିକ ଲିପିଡ୍ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, ଚର୍ମ କର୍କଟ, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା ଏବଂ ହୃଦରକ୍ତନାଳୀ ରୋଗ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୫] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ।^[୧]

ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୧୧ ମସିହାରେ ଏବଂ ୟୁରୋପରେ ୨୦୧୨ ମସିହାରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ରୁକ୍ସୋଲିଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହାରେ ଏହାର ଏକ ମାସ ବ୍ୟବ‌ହାରର ମୂଲ୍ୟ ୧୫,୮୦୦ ହୋଇଥିଲା ।^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ପରିମାଣ ଔଷଧର ମୂଲ୍ୟ ୩,୦୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୫]

ଆଧାର

1 2 3 4 5 6 7 "Jakafi- ruxolitinib tablet". DailyMed. 26 February 2020. Archived from the original on 3 November 2020. Retrieved 16 November 2020.
↑ "Jakavi EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 16 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 3 4 5 "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 12 December 2018. Retrieved 16 February 2014.
1 2 "Jakavi". Archived from the original on 12 November 2020. Retrieved 19 October 2021.
1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1056. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Jakafi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 October 2021. Retrieved 19 October 2021.

[PI2021-1] 1 2 3 4 5 6 7 "Jakafi- ruxolitinib tablet". DailyMed. 26 February 2020. Archived from the original on 3 November 2020. Retrieved 16 November 2020.

[Jakavi_EPAR-2] "Jakavi EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 16 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[MSR-3] 1 2 3 4 5 "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 12 December 2018. Retrieved 16 February 2014.

[EPAR2021-4] 1 2 "Jakavi". Archived from the original on 12 November 2020. Retrieved 19 October 2021.

[BNF80-5] 1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1056. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[6] "Jakafi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 October 2021. Retrieved 19 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]